zinc(ii)-phthalocyanine-trisulfonic-acid and Hypoxia

zinc(ii)-phthalocyanine-trisulfonic-acid has been researched along with Hypoxia* in 1 studies

Other Studies

1 other study(ies) available for zinc(ii)-phthalocyanine-trisulfonic-acid and Hypoxia

ArticleYear
Dual "Unlocking" Strategy to Overcome Inefficient Nanomedicine Delivery and Tumor Hypoxia for Enhanced Photodynamic-Immunotherapy.
    Advanced healthcare materials, 2023, Volume: 12, Issue:6

    Lacking blood vessels is one of the main characteristics of most solid tumors due to their rapid and unrestricted growth, which thus causes the inefficient delivery efficiency of nanomedicine and tumor hypoxia. Herein, a dual "unlocking" strategy to overcome these obstacles is proposed by combining engineered hybrid nanoparticles (named ZnPc@FOM-Pt) with dexamethasone (DXM). It is verified that pretreatment of tumors with DXM can increase intratumorally micro-vessel density (delivery "unlocking") to enhance the tumor delivery efficiency of ZnPc@FOM-Pt and decrease HIF-1α expression. Correspondingly, more Pt can catalyze tumor-overexpressed H

    Topics: Cell Line, Tumor; Humans; Hypoxia; Immunotherapy; Nanomedicine; Nanoparticles; Neoplasms; Photochemotherapy; Tumor Hypoxia; Tumor Microenvironment

2023